Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.99 USD | -1.32% | -3.39% | +22.49% |
05-17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.49% | 191M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q2 Revenue $3.9M, vs. Street Est of $1.6M